ES2180552T3 - Formulaciones de liberacion controlada recubiertas con dispersiones acuosas de etilcelulosa. - Google Patents

Formulaciones de liberacion controlada recubiertas con dispersiones acuosas de etilcelulosa.

Info

Publication number
ES2180552T3
ES2180552T3 ES94109115T ES94109115T ES2180552T3 ES 2180552 T3 ES2180552 T3 ES 2180552T3 ES 94109115 T ES94109115 T ES 94109115T ES 94109115 T ES94109115 T ES 94109115T ES 2180552 T3 ES2180552 T3 ES 2180552T3
Authority
ES
Spain
Prior art keywords
agent
exposure
formulation
etilcellulose
waterproof
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94109115T
Other languages
English (en)
Inventor
Benjamin Oshlack
Mark Chasin
Frank Pedi Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22165285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2180552(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of ES2180552T3 publication Critical patent/ES2180552T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

UNA FORMULACION SOLIDA ESTABILIZADA DE LIBERACION CONTROLADA QUE TIENE UNA CUBIERTA DERIVADA DE UNA DISPERSION ACUOSA DE UN POLIMERO HIDROFOBICO ES OBTENIDA POR SOBRECUBRIR UN SUBSTRATO QUE INCLUYE UN AGENTE ACTIVO SELECCIONADO DEL GRUPO QUE CONSTA DE UN AGENTE TERAPEUTICO SISTEMATICAMENTE ACTIVO, UN AGENTE TERAPEUTICO LOCALMENTE ACTIVO, UN DESINFECTANTE Y UN AGENTE SANEADOR, UN AGENTE LIMPIADOR, UN AGENTE AROMATICO Y UN AGENTE FERTILIZADOR, CON UNA DISPERSION ACUOSA DEL POLIMERO HIDROFOBICO PLASTIFICADO, HASTA QUE ES ALCANZADO UN PUNTO FINAL DE CURACION AL CUAL EL SUBSTRATO CUBIERTO PROVEE UNA DISOLUCION ESTABILIZADA DEL AGENTE ACTIVO QUE ES DESCAMBIADO DESPUES DE LA EXPOSICION A LAS CONDICIONES DE ALMACENAJE ACELERADAS, SIENDO EL PUNTO FINAL DETERMINADO POR COMPARAR EL PERFIL DE DISOLUCION DE LA FORMULACION INMEDIATAMENTE DESPUES DE LA CURACION AL PERFIL DE DISOLUCION DE LA FORMULACION DESPUES DE LA EXPOSICION A LAS CONDICIONES DE ALMACENAJE ACELERADAS DE AL MENOS UN MES A UNA TEMPERATURADE 37 C Y A UNA HUMEDAD RELATIVA DEL 80%.
ES94109115T 1993-06-23 1994-06-14 Formulaciones de liberacion controlada recubiertas con dispersiones acuosas de etilcelulosa. Expired - Lifetime ES2180552T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/081,618 US5472712A (en) 1991-12-24 1993-06-23 Controlled-release formulations coated with aqueous dispersions of ethylcellulose

Publications (1)

Publication Number Publication Date
ES2180552T3 true ES2180552T3 (es) 2003-02-16

Family

ID=22165285

Family Applications (3)

Application Number Title Priority Date Filing Date
ES04018826T Expired - Lifetime ES2315599T3 (es) 1993-06-23 1994-06-14 Formulaciones de liberacion controlada recubiertas con dispersiones acuosas de etilcelulosa.
ES04003055T Expired - Lifetime ES2252711T3 (es) 1993-06-23 1994-06-14 Formulaciones de liberacion controlada recubiertas con dispersiones acuosas de etilcelulosa.
ES94109115T Expired - Lifetime ES2180552T3 (es) 1993-06-23 1994-06-14 Formulaciones de liberacion controlada recubiertas con dispersiones acuosas de etilcelulosa.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES04018826T Expired - Lifetime ES2315599T3 (es) 1993-06-23 1994-06-14 Formulaciones de liberacion controlada recubiertas con dispersiones acuosas de etilcelulosa.
ES04003055T Expired - Lifetime ES2252711T3 (es) 1993-06-23 1994-06-14 Formulaciones de liberacion controlada recubiertas con dispersiones acuosas de etilcelulosa.

Country Status (14)

Country Link
US (1) US5472712A (es)
EP (9) EP1504758A3 (es)
JP (3) JP4505059B2 (es)
AT (3) ATE221375T1 (es)
AU (2) AU680491B2 (es)
CA (1) CA2125904C (es)
DE (3) DE69431089T2 (es)
DK (3) DK1477162T3 (es)
ES (3) ES2315599T3 (es)
FI (1) FI121620B (es)
HK (1) HK1048432A1 (es)
NO (1) NO314566B1 (es)
PT (2) PT630646E (es)
SI (2) SI1419766T1 (es)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
EP1442745A1 (en) 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
CA2223768A1 (en) * 1995-06-09 1996-12-27 R.P. Scherer Corporation Suspension and soft gelatin capsules containing particulate matter
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5939356A (en) * 1996-06-21 1999-08-17 Southwest Research Institute Controlled release coated agricultural products
US6238704B1 (en) * 1996-09-13 2001-05-29 Shionogi & Co., Ltd. Sustained-release preparation utilizing thermal change and process for the production thereof
US5807580A (en) * 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
US6180128B1 (en) * 1997-01-27 2001-01-30 C-Cure Corp. Non-carcinogenic substitute for play sand
PT1009387E (pt) 1997-07-02 2006-08-31 Euro Celtique Sa Formulacoes estabilizadas de libertacao controlada de tramadol
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
CA2306215C (en) * 1997-10-15 2010-06-22 University Of South Florida Supercritical fluid aided coating of particulate material
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US6485748B1 (en) * 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US5976507A (en) * 1998-06-04 1999-11-02 Colgate Palmolive Company Dentrifice composition containing encapsulated reactive ingredients
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19901686A1 (de) 1999-01-18 2000-07-20 Gruenenthal Gmbh Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
WO2001019901A2 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP1935421A1 (en) 2000-02-08 2008-06-25 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
GB0007419D0 (en) † 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
SE0001151D0 (sv) * 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6663686B1 (en) 2000-06-27 2003-12-16 Agrium, Inc. Controlled release fertilizer and method for production thereof
AU2738302A (en) * 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
BR0115585A (pt) 2000-11-28 2005-12-13 Fmc Corp Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US6486248B2 (en) 2001-01-08 2002-11-26 Milliken & Company Liquid colorant and method
US6878309B2 (en) * 2001-02-12 2005-04-12 Dober Chemical Corp. Controlled release cooling additive composition
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1429728A1 (en) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
JP4925526B2 (ja) * 2001-09-10 2012-04-25 旭化成ケミカルズ株式会社 薬物の混合方法
US8282955B2 (en) 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
FR2832632B1 (fr) 2001-11-26 2004-04-23 Mane Fils V Capsule a solubilisation et liberation du contenu rapides
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
BR0312876A (pt) * 2002-07-25 2005-06-28 Pharmacia Corp Método de preparação de formas de dosagem sólidas revestidas em duas camadas compreendendo um polìmero insolúvel em água e um agente formador de poros solúvel em água
US20040016276A1 (en) * 2002-07-26 2004-01-29 Wynnyk Nick P. Controlled release fertilizer having improved mechanical handling durability and method for production thereof
DE60335426D1 (de) 2002-08-15 2011-01-27 Euro Celtique Sa Pharmazeutische Zusammensetzungen enthaltend einen Opioidantagonisten
US20040043064A1 (en) * 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
AU2003267231A1 (en) * 2002-09-20 2004-04-08 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
ES2206047B1 (es) * 2002-10-22 2005-08-01 Universidad De Granada Sintesis de un transportador de morfina para formas farmaceuticas liquidas orales de accion controlada.
AU2003295846A1 (en) * 2002-11-26 2004-06-18 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
EP1615625A4 (en) 2003-04-21 2010-12-15 Euro Celtique Sa SAFETY DOSING FORM WITH COEXTRUDED PARTICLES OF AN UNWANTED MEDIUM AND METHOD OF MANUFACTURING THEREOF
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
CA2520197A1 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
GB2402679A (en) * 2003-06-10 2004-12-15 Reckitt Benckiser Nv Automatic washing machine detergent dispensing device
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
FR2859729B1 (fr) * 2003-09-12 2006-02-24 Roquette Freres Dispersions aqueuses d'au moins un polymere biodegradable
EP1663229B1 (en) 2003-09-25 2010-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
CA2548834C (en) * 2003-12-09 2009-08-11 Euro-Celtique S.A. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
EP1547601A1 (en) * 2003-12-23 2005-06-29 Ferring B.V. Coating method
RS50817B (sr) * 2004-03-30 2010-08-31 Euro-Celtique S.A. Dozni oblik otporan na promene koji sadrži adsorbenti i sredstvo sa suprotnim dejstvom
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
CA2916869A1 (en) 2004-06-12 2005-12-29 Jane C. Hirsh Abuse-deterrent drug formulations
CN101022788B (zh) * 2004-08-13 2010-11-10 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
UA93608C2 (ru) * 2004-08-13 2011-02-25 Берингер Ингельхайм Интернациональ Гмбх композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
JP4997109B2 (ja) 2004-09-01 2012-08-08 ユーロ−セルティーク エス．エイ． 用量比例的な定常状態ｃａｖｅおよび定常状態ａｕｃ、ならびに、用量比例よりも小さい単回投与ｃｍａｘを有するオピオイド投薬形態物
US20060093629A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
GB0427455D0 (en) * 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
CN101111245A (zh) * 2005-01-27 2008-01-23 阿雷姆贝克有限公司 左乙拉西坦延长释放制剂
CA2594373A1 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1754471A1 (de) 2005-08-18 2007-02-21 ORAMON-Arzneimittel GmbH & Co. KG Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
WO2007092718A2 (en) * 2006-02-07 2007-08-16 Fmc Corporation Coating process to produce controlled release coatings
EP1988875A2 (en) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modified release formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
WO2008083709A1 (en) * 2007-01-10 2008-07-17 Bayer Cropscience Ag Insecticidal fertilizer mixtures
US7879747B2 (en) 2007-03-30 2011-02-01 Kimberly-Clark Worldwide, Inc. Elastic laminates having fragrance releasing properties and methods of making the same
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
HUE073014T2 (hu) 2007-04-25 2025-12-28 Opko Renal Llc Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US8007707B1 (en) 2007-05-15 2011-08-30 Fresh Products, Inc. Method of manufacture air freshening article
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
RS51313B (sr) * 2007-11-09 2010-12-31 Acino Pharma Ag.51311 Retard tablete sa hidromorfonom
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
EP2281058B1 (en) 2008-04-02 2016-06-29 Opko Ireland Global Holdings, Ltd. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
US8404260B2 (en) * 2008-04-02 2013-03-26 Bayer Cropscience Lp Synergistic pesticide compositions
DE102008021473A1 (de) * 2008-04-29 2009-11-12 Heraeus Kulzer Gmbh Mit Antiplaque-Wirkstoff(en) ausgestattete Dentalmaterialien
US7883638B2 (en) 2008-05-27 2011-02-08 Dober Chemical Corporation Controlled release cooling additive compositions
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010053337A2 (ko) * 2008-11-10 2010-05-14 (주)아모레퍼시픽 서방성 미립자 및 이의 제조방법
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
US20120090366A1 (en) * 2010-04-16 2012-04-19 Taylor Pursell Controlled release fertilizer with biopolymer coating and process for making same
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
JP6272695B2 (ja) * 2010-09-01 2018-01-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形
ME02874B (me) 2010-12-22 2018-04-20 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
ES2628303T3 (es) * 2011-06-01 2017-08-02 Fmc Corporation Formas de dosis sólidas de liberación controlada
US9243394B2 (en) 2011-09-20 2016-01-26 Fresh Products, Inc. Replaceable restroom urinal assemblies, including urinal screens
ES2663744T3 (es) * 2011-10-06 2018-04-16 Novartis Ag Composiciones farmacéuticas que comprenden 40-O-(2-hidroxi)etil-rapamicina
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
KR102082529B1 (ko) 2012-04-17 2020-02-27 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
EP2872516B1 (en) 2012-07-16 2017-08-30 Rhodes Technologies Process for improved opioid synthesis
KR101946104B1 (ko) 2012-07-16 2019-02-08 로드스 테크놀로지즈 개선된 오피오이드 합성을 위한 방법
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA2919602C (en) 2013-08-02 2018-03-13 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
KR101868723B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시코돈 합성을 위한 방법
EP3094633B1 (en) 2014-01-15 2018-03-14 Rhodes Technologies Process for improved oxymorphone synthesis
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
EP2937096B1 (en) 2014-04-23 2019-08-21 Julius-Maximilians-Universität Würzburg Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity
US20180104197A9 (en) * 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
MX2016014320A (es) 2014-05-01 2017-05-23 Sun Pharmaceutical Ind Ltd Composiciones de suspension de liberacion prolongada.
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
EP3139924A4 (en) 2014-05-06 2018-03-07 Anthony G. Visco Methods of treating or preventing preterm labor
BR112017001968A2 (pt) 2014-07-30 2017-11-21 Sun Pharmaceutical Ind Ltd embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
DE202015102279U1 (de) 2014-11-05 2015-08-14 Fresh Products, Inc. Urinalsieb
USD778411S1 (en) 2014-11-05 2017-02-07 Fresh Products, Inc. Urinal screen
USD778412S1 (en) 2014-11-10 2017-02-07 Fresh Products, Inc. Urinal screen
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
CA2986359A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
CA3075292A1 (en) * 2017-10-20 2019-04-25 Purdue Pharma L.P. Pharmaceutical dosage forms
CA3084992A1 (en) 2017-12-20 2019-06-27 Fresh Products, Inc. Urinal screens
EP3727384A4 (en) 2017-12-20 2021-11-03 Purdue Pharma L.P. ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
EP3594194A1 (en) 2018-07-12 2020-01-15 Casale Sa Urea granulation process
CN108958335B (zh) * 2018-07-27 2021-08-24 中国兵器工业第五九研究所 一种气候模块化数控贮存试验系统
USD925009S1 (en) 2018-10-25 2021-07-13 Fresh Products, Inc. Urinal screen
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
KR20220161342A (ko) * 2020-04-13 2022-12-06 에이케이아이, 인크. 일회용 디퓨징 칼라 스테이
WO2022167359A1 (en) 2021-02-02 2022-08-11 DuPont Nutrition USA, Inc. An aqueous gel composition comprising an ethylcellulose
USD1078945S1 (en) 2022-07-13 2025-06-10 Fresh Products, Inc. Urinal screen
CN115844854B (zh) * 2022-10-26 2025-02-18 沈阳药科大学 一种微囊型自悬浮茶碱缓释颗粒及其制备方法
CN119139256B (zh) * 2024-09-14 2025-05-27 安徽瑞旗药业有限公司 一种富马酸依美斯汀制剂及其制备方法
CN121058684A (zh) * 2025-08-27 2025-12-05 湖南农业大学 一种定时释放农药及其制备方法和应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567650A (en) * 1969-02-14 1971-03-02 Ncr Co Method of making microscopic capsules
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
JPS60166608A (ja) * 1984-02-08 1985-08-29 Japan Atom Energy Res Inst サンドイツチ構造をもつ徐放性複合体およびその製造方法
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4849229A (en) * 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
GB2170104A (en) * 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1214629B (it) * 1985-08-29 1990-01-18 Formenti Farmaceutici Spa Procedimento di microincapsulazione di un medicamento,medicamento cosi'preparato,e composizioni farmaceutiche che lo comprendono
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4837004A (en) * 1985-10-18 1989-06-06 Eastman Kodak Company Rumen-stable pellets
IT1204294B (it) * 1986-03-11 1989-03-01 Gentili Ist Spa Metodo di fabbricazione di granulari atti a produzione di compresse rivestite,per uso orale,a rilascio controllato
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4810501A (en) * 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
JP2668880B2 (ja) * 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US5219621A (en) * 1987-10-16 1993-06-15 Elan Corporation, Plc Methods of treatment with diltiazem formulations
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US4837033A (en) * 1987-12-22 1989-06-06 Shin-Etsu Chemical Co., Ltd. Method for the preparation of a coated solid medicament
US5064650A (en) * 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US4983730A (en) * 1988-09-02 1991-01-08 Hoechst Celanese Corporation Water soluble cellulose acetate composition having improved processability and tensile properties
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5085866A (en) * 1988-12-02 1992-02-04 Southern Research Institute Method of producing zero-order controlled-released devices
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US5047258A (en) * 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
JPH0361474A (ja) * 1989-07-31 1991-03-18 Izumi Enterp:Kk 清酒又はブドウ酒を、風味を損なわずに希釈して、低濃度のアルコール飲料とするために用いる割り水
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
IL96311A (en) * 1989-12-01 1995-05-26 Abbott Lab Medications with delayed release
US5077053A (en) * 1990-02-12 1991-12-31 Warner-Lambert Company Zein as a moisture barrier for sugarless edible compositions and method for preparing same
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2036907C (en) * 1990-02-28 1996-10-22 Yuzo Miura 3-(substituted phenyl) pyrazole derivatives, a process for producing the same, herbicidal composition containing the same and method of controlling weeds using said composition
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
US5042842A (en) * 1990-06-26 1991-08-27 Avery International Corporation High security label
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning

Also Published As

Publication number Publication date
EP2018852A1 (en) 2009-01-28
SI1419766T1 (sl) 2006-04-30
EP1502591A3 (en) 2006-02-08
FI943022A0 (fi) 1994-06-22
CA2125904A1 (en) 1994-12-24
EP1203581A2 (en) 2002-05-08
EP1477162A1 (en) 2004-11-17
JP4505059B2 (ja) 2010-07-14
CA2125904C (en) 2000-08-08
EP1504758A3 (en) 2006-04-12
JPH07138189A (ja) 1995-05-30
EP0630646B1 (en) 2002-07-31
JP2006188540A (ja) 2006-07-20
DE69431089T2 (de) 2003-03-27
DE69435145D1 (de) 2008-11-06
EP1475085A1 (en) 2004-11-10
DE69434515D1 (de) 2006-03-02
DK1419766T3 (da) 2006-03-06
EP1203581A3 (en) 2002-12-11
EP1502591A2 (en) 2005-02-02
NO942382D0 (es) 1994-06-22
US5472712A (en) 1995-12-05
AU704524B2 (en) 1999-04-29
AU6484694A (en) 1995-01-19
NO314566B1 (no) 2003-04-14
EP1477162B1 (en) 2008-09-24
AU4368797A (en) 1998-01-22
ATE306909T1 (de) 2005-11-15
ATE409024T1 (de) 2008-10-15
EP1419766A1 (en) 2004-05-19
ES2315599T3 (es) 2009-04-01
JP4703471B2 (ja) 2011-06-15
EP1504758A2 (en) 2005-02-09
EP1504757A2 (en) 2005-02-09
ATE221375T1 (de) 2002-08-15
EP0630646A1 (en) 1994-12-28
DE69431089D1 (de) 2002-09-05
NO942382L (no) 1994-12-27
DK0630646T3 (da) 2002-11-25
FI121620B (fi) 2011-02-15
JP4703470B2 (ja) 2011-06-15
EP1504757A3 (en) 2006-04-12
SI1477162T1 (sl) 2009-02-28
JP2006188539A (ja) 2006-07-20
ES2252711T3 (es) 2006-05-16
PT630646E (pt) 2002-12-31
AU680491B2 (en) 1997-07-31
DK1477162T3 (da) 2009-01-12
DE69434515T2 (de) 2006-07-06
PT1477162E (pt) 2008-12-17
HK1048432A1 (en) 2003-04-04
FI943022L (fi) 1994-12-24
EP1419766B1 (en) 2005-10-19

Similar Documents

Publication Publication Date Title
ES2180552T3 (es) Formulaciones de liberacion controlada recubiertas con dispersiones acuosas de etilcelulosa.
BR0208147A (pt) Processo de controle da liberação de ingredientes agrìcolas ativos de sementes de plantas tratadas
DK0574541T3 (da) Svovlovertrukne gødningsstoffer samt fremgangsmåde til deres fremstilling
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
BRPI0409348A (pt) formulações e métodos para tratamento de rinossinusite
BR9206387A (pt) Composições de spray para o cabelo
ATE150616T1 (de) Verabreichungszusammensetzungen für unkrautvertilgungsmittel sowie verfahren zur regelung der pflanzenbevölkerung in wässriger und sumpfähnlicher umgebung
ATE201590T1 (de) Zusammensetzung mit verzögerter freisetzung
BR0110738A (pt) Combinações de agentes protetores de plantas com materiais veìculos orgânicos ou inorgânicos
ES2139877T3 (es) Agente anti-incrustacion.
MXPA03006999A (es) Composicion limpiadora espumante suave.
UY26938A1 (es) Tratamiento de semillas con recubrimiento que contienen hidrogel
DE69914320T2 (de) Verfahren zur herstellung einer mit bändern versehenen dosisform zur verlängerten freisetzung eines wirkstoffs
ES2082735T3 (es) Producto para el tratamiento del cabello y procedimiento para su utilizacion.
DK0703726T3 (da) Stabile vandige sammensætninger af 1,2-benzthiazolin-3-on samt anvendelser af samme
BR0112770A (pt) Agentes herbicidas
ES2158292T3 (es) Composicion para controlar parasitos.
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
ES2108619B1 (es) Composicion insecticida/acaricida.
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
ES2068797T3 (es) Producto para el tratamiento del cabello y procedimiento para su aplicacion.
CO4340720A1 (es) Asociaciones de un fungicida que tiene grupo azol con un insecticida que tiene grupo pirazol, pirrol o fenilimidazol y composiciones de estas asociaciones . .
BR0100876A (pt) Composição pesticida aquosa
ATE337705T1 (de) Wässrige zusammensetzungen enthaltend eine haloalkynyl-verbindung und einen puffer zur verleihung biozider eigenschaften und zur stabilisierung der endformulierungen
DK0378303T3 (da) Undertrykkelse af mercaptanluft fra organothiophosphatbiocider